Expanding Indications from Post-Treatment to Relapse Management

Onconic Therapeutics has begun clinical trials to expand the treatment scope of its erosive gastroesophageal reflux disease (GERD) therapy, Zacubo (ingredient: zastaprazan), from 'acute phase treatment' to 'relapse management.' If the company successfully obtains an indication for maintenance therapy, both the prescription period and dosage would be increased, thereby enhancing the product's competitiveness.

Onconic Therapeutics Research Institute Exterior. Onconic Therapeutics

Onconic Therapeutics Research Institute Exterior. Onconic Therapeutics

View original image

On April 1, Onconic Therapeutics announced that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety for a Phase 3 clinical trial to obtain an indication for 'maintenance therapy after treatment of erosive gastroesophageal reflux disease' for Zacubo, a P-CAB class GERD treatment (zastaprazan).


This clinical trial aims to secure an indication for maintenance therapy that suppresses symptom recurrence after treatment. GERD is a chronic recurrent disease, and frequent symptom recurrence following treatment discontinuation has led to a consistent need for long-term management.


The clinical trial is designed based on a low dose of 10mg, which is half of the existing treatment dose of 20mg. Efficacy and safety will be evaluated in a long-term dosing environment for up to six months. If the indication is added, Zacubo will be expanded to a treatment that covers not only acute phase therapy but also maintenance therapy.


Zacubo was approved as a treatment for erosive GERD in 2024, and an additional indication for gastric ulcer was obtained in 2025. Currently, Phase 3 clinical trials are underway for the prevention of NSAID-induced ulcers and for a non-erosive GERD indication. In January of this year, the company also launched an orodispersible tablet formulation.


The company is also pursuing global expansion. In August 2025, Chinese partner Livzon applied for product approval to the National Medical Products Administration of China. The milestone payment related to this has already been received. The company expects that the results from this maintenance therapy clinical trial will provide evidence that can be used for future overseas approvals and commercialization.



An official from Onconic Therapeutics said, "The maintenance therapy clinical trial is expected to serve as a foundation for market expansion in terms of both prescription period and dosage."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing